THE PRECISION APROACH
: MOLECULAR TARGET
2008
2011
TIME LINE
KRAS mutation
and benefit from
CETUXIMAB
in advanced colorectal cancer.
Karapetis CS. N Engl J Med. 2008
Wild-type KRAS
is required for
PANITUMUMAB
efficacy in...metastatic colorectal cancer.
Amado RG J Clin Oncol 2008
HYPOTHESIS
: Retrospective analysis KRAS
mutational status
EXON 2
(codons 12-13)
KRASwt KRASmut
12,8% 1,2%
17% 0%
22
